FDA slams Reata's kid­ney drug as in­ef­fec­tive ahead of ad­comm meet­ing

The FDA on Mon­day of­fered an over­whelm­ing­ly neg­a­tive opin­ion on Rea­ta Phar­ma­ceu­ti­cals’ po­ten­tial drug to slow the loss of kid­ney func­tion in those with the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER